Status:
ACTIVE_NOT_RECRUITING
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Myelofibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Pr...
Eligibility Criteria
Inclusion
- Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis
- Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment
- Must agree to follow specific methods of contraception, if applicable
Exclusion
- Women who are pregnant or breastfeeding at screening
- Any significant acute or uncontrolled chronic medical illness
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT04817007
Start Date
March 22 2021
End Date
May 31 2026
Last Update
September 10 2025
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0069
Newport Beach, California, United States, 92663
2
Local Institution - 0090
Lake Mary, Florida, United States, 32746
3
Local Institution - 0043
New Orleans, Louisiana, United States, 70112
4
Local Institution - 0038
Worcester, Massachusetts, United States, 01655